Papillary Dermal Elastolysis Secondary to Combination Nivolumab and Cabiralizumab Therapy: Histiocytes and Dermal Mucin as Clues to the Diagnosis. (3rd October 2021)

• Record Type: Journal Article
• Authors: Yin, Lu; Criscito, Maressa C.; Stokar, Evan; Siolas, Despina; Haimovic, Adele; Lo Sicco, Kristen; Brinster, Nooshin K.
• Is Part Of: American journal of dermatopathology. Volume 43:Number 10(2021)
• Page Start: 746
• Page End: 749
• Publication Date: 2021-10-03
• Subjects: dermal elastolysis -- immunotherapy -- nivolumab -- cabiralizumab; Skin -- Diseases -- Periodicals; Histology, Pathological -- Periodicals; 616.50705
• DOI: 10.1097/DAD.0000000000001915
• Languages: English
• ISSNs: 0193-1091

Abstract

Abstract: Papillary dermal elastolysis has been described in the setting of experimental combination nivolumab and cabiralizumab immunotherapy. We report a third patient with distinctive, generalized atrophic macules that developed after a morbilliform eruption during a clinical trial for treatment of metastatic pancreatic adenocarcinoma. Histopathological findings demonstrated diminished elastic fibers in the papillary dermis, associated with a histiocyte-rich infiltrate and increased dermal mucin, features that should clue the dermatopathologist to this condition.